Rhein Minapharm Biogenetics/Minapharm Pharmaceuticals

About us
Minapharm, headquartered in Cairo with its production facilities in the 10th of Ramadan, is among the leading prescription medicine companies in Egypt and the Middle East. The company is specialized in the manufacture and marketing of innovative pharmaceuticals and through its subsidiary Rhein-Minapharm-Biogenetics, in the research, development and manufacturing of biopharmaceuticals. Its biotech subsidiary is focussing on the core therapeutic areas of liver disease and thrombosis & haemostasis. With six therapeutic proteins [PEG-IFN alfa 2a, Hirudin (creme, gel, injectable) and FSH (2 different dosages)] already marketed and several in the pipeline, Minapharm’s competence lies in decreasing time to market without compromising ethical and safety standards. Our development pipeline consists currently of about 10 receombinant protein candidates.

By combining its expertise in pharmaceuticals and leadership in biopharmaceuticals Minapharm, along with its worldwide strategic alliances, contributes significantly to the quality of life of many people in the region. Minapharm employs a collective workforce of over 700 and is listed on the Cairo and Alexandria stock exchange ( Symbol: MIPH ). For more information on Minapharm and its products please visit www.minapharm.com and www.rhein-minapharm.com.
In June 2010 Minapharm aquired the german company ProBioGen AG (www.probiogen.de) located in Berlin.